About the program
Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune disease characterized by a variable and often progressive trajectory, which frequently leads to cirrhosis and liver failure.
The management approach for PBC emphasizes a personalized strategy that begins with an early assessment of an individual’s risk profile, as well as considering the timely incorporation of second-line drugs, especially for those at high risk. Importantly, there are multiple approvals on the horizon and several agents in late-stage development which could lead to a paradigm shift in the management of this disease.
This expert-led program will allow you to effectively evaluate treatment response in your patients, and make informed decisions on individualized patient management strategies, regarding therapy response, symptom management, clinical guidelines, and new advances in the PBC treatment landscape.
Learning Objectives
Following completion of this independent educational program, you will be able to:
- Evaluate first-line treatment response and identify individuals who could benefit from initiating second-line therapy
- Implement clinical guidelines recommendations to optimize the management and monitoring of the symptoms of PBC
- Analyze recent advances in the treatment landscape of PBC and their impact on clinical practice
Target Audience
This program is primarily aimed at a global audience of hepatologists and gastroenterologists, and is relevant to all members of the multidisciplinary team that manages PBC patients.
Planning Committee
In addition to the expert faculty Springer Healthcare IME planners and staff include Rachel Goddard, Jaia Golby-Meek, Alba Ruzafa, and Lucy Piper. The planning committee have no financial relationships to disclose.
All relevant financial relationships of the faculty have been mitigated.
